Mutagenesis · 2005 · 13 citations · 36 references
PharmacyPharmacologyToxicologyAnalytical ToxicologyHepatotoxicologyMolecular ToxicologyBioanalytical Method ValidationRodent ToxicologyAnalytical Liquid ChromatographyDna Adduct DosimetryDna Adduct MeasurementDna Adduct QuantificationDna Oxidative Adducts
Liver homogenates from rats fed tamoxifen (TAM) in the diet were shared among four different laboratories. TAM-DNA adducts were assayed by high pressure liquid chromatography-electrospray tandem mass spectrometry (HPLC-ES-MS/MS), TAM-DNA chemiluminescence immunoassay (TAM-DNA CIA), and (32)P-postlabeling with either thin layer ((32)P-P-TLC) or liquid chromatography ((32)P-P-HPLC) separation. In the first study, rats were fed a diet containing 500 p.p.m. TAM for 2 months, and the values for measurements of the (E)-alpha-(deoxyguanosin-N(2)-yl)-tamoxifen (dG-N(2)-TAM) adduct in replicate rat livers varied by 3.5-fold when quantified using 'in house' TAM-DNA standards, or other approaches where appropriate. In the second study, rats were fed 0, 50, 250 or 500 p.p.m. TAM for 2 months, and TAM-DNA values were quantified using both 'in house' approaches as well as a newly synthesized [N-methyl-(3)H]TAM-DNA standard that was shared among all the participating groups. In the second study, the total TAM-DNA adduct values varied by 2-fold, while values for the dG-N(2)-TAM varied by 2.5-fold. Ratios of dG-N(2)-TAM:(E)-alpha-(deoxyguanosin-N(2)-yl)-N-desmethyltamoxifen (dG-N(2)-N-desmethyl-TAM) in the second study were approximately 1:1 over the range of doses examined. The study demonstrated a remarkably good agreement for TAM-DNA adduct measurements among the diverse methods employed.
36
Tamoxifen for early breast cancer: an overview of the randomised trials
The Lancet · 1998 · 4.1K citations
Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats.
Peter Greaves, Rajiv Goonetilleke, Graham R. Nunn et al. · PubMed · 1993 · 303 citations
Medicine, Pharmacology, Toxicology +17